Newron Pharmaceuticals has agreed to acquire NeuroNova in an all-share deal that values the Swedish company at €15.4 M (US$19.2 M). With the acquisition, Newron will gain a portfolio of CNS products, including two compounds in Phase II development for Parkinson’s disease and amyotrophic lateral sclerosis, respectively. Newron will also benefit from cash and commitments of up to €16 M (US$20 M) at the close of the deal.